IP Library Granted Patent US 11,857,326
Granted Patent B2
US 11,857,326 · App. 16/812,702 · Granted Jan 2, 2024

Agent-delivering neural probe devices and related systems and methods

Inventors: Dave Rosa (Eden Prairie, MN); Thomas Bachinski (Lakeville, MN)
Assignee: NeuroOne Medical Technologies Corporation
A61B5/24A61N1/0529A61B5/6868A61B2562/0209
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,857,326
App. No.
16/812,702
Granted
Jan 2, 2024
Kind
B2
Abstract

Provided herein are a variety of neural probe devices that include an agent delivery feature via an agent coating or an agent delivery mechanism of some kind. The probe devices can include depth or cortical probes or electrodes. The agent delivery mechanisms can include, for example, a dissolvable agent delivery structure, an agent delivery lumen, a magnetically deployable cover, an iontophoretic delivery mechanism, an agent delivery cavity defined in the neural probe, or an agent reservoir with an actuable gate.

Claims (31)

1. A neural electrode comprising:

(a) an electrode body;

(b) at least one electrode array associated with the electrode body; and

(c) a dissolvable agent delivery structure releasably disposed over at least a portion of the electrode body such that the dissolvable agent delivery structure is configured to separate from the electrode body and remain in a treatment position upon removal of the electrode body.

2. The neural electrode of claim 1 , wherein the dissolvable agent delivery structure is configured to deliver a treatment agent over a predetermined period of time following removal of the electrode body.

3. The neural electrode of claim 1 , wherein the dissolvable agent delivery structure comprises a dissolvable scaffold comprising at least one treatment agent.

4. The neural electrode of claim 3 , wherein the at least one treatment agent is releasable over time as the dissolvable scaffold dissolves.

5. The neural electrode of claim 3 , wherein the at least one treatment agent comprises a cannabinoid.

6. The neural electrode of claim 1 , wherein the electrode body comprises an elongate, unitary tubular body, wherein the at least one electrode array is disposed on an outer surface of the tubular body, and wherein the neural electrode is a depth electrode.

7. The neural electrode of claim 1 , further comprising an elongate structure coupled to the electrode body, wherein the electrode body comprises a thin film pad, wherein the at least one electrode array is disposed in the thin film pad, and wherein the neural electrode is a cortical electrode.

8. A neural electrode comprising:

(a) an electrode body;

(b) at least one electrode associated with the electrode body; and

(c) a dissolvable agent delivery structure releasably disposed over at least a portion of the electrode body such that the dissolvable agent delivery structure is configured to be deployed with the electrode body and then released from the electrode body, and to remain in a treatment position upon removal of the electrode body.

9. The neural electrode of claim 8 , wherein the dissolvable agent delivery structure is configured to deliver a treatment agent over a predetermined period of time following removal of the electrode body.

10. The neural electrode of claim 8 , wherein the dissolvable agent delivery structure comprises a dissolvable scaffold comprising at least one treatment agent.

11. The neural electrode of claim 10 , wherein the at least one treatment agent is releasable over time as the dissolvable scaffold dissolves.

12. The neural electrode of claim 10 , wherein the at least one treatment agent comprises a cannabinoid.

13. The neural electrode of claim 8 , wherein the electrode body comprises an elongate, unitary tubular body, and wherein the at least one electrode is disposed on an outer surface of the tubular body, and wherein the neural electrode is a depth electrode.

14. The neural electrode of claim 8 , further comprising an elongate structure coupled to the electrode body, wherein the electrode body comprises a thin film pad, wherein the at least one electrode is disposed in the thin film pad, and wherein the neural electrode is a cortical electrode.

15. The neural electrode of claim 14 wherein the elongate structure comprises a proximal end, a distal end, and a fluid channel extending from the proximal end to the distal end, wherein the distal end of the elongate structure is coupled to the electrode body.

16. The neural electrode of claim 15 wherein the fluid channel is in fluid communication with a drug delivery lumen defined in a portion of the electrode body.

17. The neural electrode of claim 14 further comprising an agent elution coating disposed on the electrode body.

18. A method of using a neural electrode, the method comprising:

(a) providing the neural electrode, the neural electrode comprising:

(i) an electrode body;

(ii) at least one electrode array associated with the electrode body; and

(iii) a dissolvable agent delivery structure releasably disposed over at least a portion of the electrode body such that the dissolvable agent delivery structure is configured to release from the electrode body and remain in a treatment position upon removal of the electrode body;

(b) deploying the electrode body and the dissolvable agent delivery structure to the treatment position;

(c) releasing the dissolvable agent delivery structure from the electrode body; and

(d) removing the electrode body from the treatment position.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 12, 2024
From: GROWTH OPPORTUNITY FUNDING, LLC
To: NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Reel/Frame 069228/0817 →
SECURITY INTEREST Recorded Aug 6, 2024
From: NEUROONE MEDICAL TECHNOLOGIES CORPORATION
To: GROWTH OPPORTUNITY FUNDING, LLC
Reel/Frame 068197/0166 →
CHANGE OF NAME Recorded May 4, 2020
From: NEUROONE, INC.
To: NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Reel/Frame 052557/0923 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2020
From: ROSA, DAVE; BACHINSKI, THOMAS
To: NEUROONE, INC.
Reel/Frame 052052/0766 →
Continuity (2)
Provisional Application 62815530 · Mar 8, 2019
Related Publication 20200281489A1 · Sep 10, 2020